Clinical Trial Update: Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety, tolerability, and immunoregulatory activity of mogamulizumab (KW-0761) in patients with advanced or metastatic solid tumors h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Mogamulizumab (mogamulizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-04-23